Newly approved cancer drugs in China — innovation and clinical benefit

Nature Reviews Clinical Oncology, Published online: 16 January 2023; doi:10.1038/s41571-023-00728-3Around 100 new cancer drugs, defined as new molecular entities, were approved in China between 2005 and 2021. More than half of these new cancer drugs do not constitute innovations in mechanism of action or therapy and do not have documented meaningful clinical benefit. Approaches are needed to promote meaningful innovation for patients with cancer.
Source: Nature Reviews Clinical Oncology - Category: Cancer & Oncology Authors: Source Type: research